RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort

ResMed received FDA clearance for Personalized Therapy Comfort Settings (branded Smart Comfort), the first FDA-cleared AI-enabled device to recommend individualized CPAP comfort settings; it will launch in a limited U.S. myAir beta with AirSense 11 devices in early 2026 and expand more broadly later that year. Built on more than 100 million nights of de-identified sleep data and supported by retrospective real-world evidence showing higher engagement and sustained adherence versus defaults, Smart Comfort is positioned to improve patient initiation and long-term CPAP use while reducing manual setup and follow-up burden for clinicians. The announcement briefly pressured the stock (down 2.5% to $250.04) despite ResMed’s $37.44bn market cap and a Zacks consensus FY2026 EPS growth estimate of 13.2%; given a large and growing addressable market (roughly 61m U.S. OSA patients today, $7.11bn global device market in 2025, ~7% CAGR to 2034), the product could support adoption, therapy efficacy and longer-term revenue upside if clinical and commercial rollout succeeds.

Analysis

ResMed secured FDA clearance for Personalized Therapy Comfort Settings (branded Smart Comfort), the first FDA-cleared AI-enabled medical device to recommend individualized CPAP comfort settings; the company plans a limited U.S. myAir beta with AirSense 11 devices in early 2026 and a broader U.S. rollout later that year. Smart Comfort leverages more than 100 million nights of de‑identified sleep data and inputs such as age, gender and AHI to tailor pressure ramp and exhale relief, aiming to address initial comfort and mask-fit barriers to therapy initiation.

The FDA filing was supported by retrospective real‑world evidence showing higher engagement and sustained adherence versus default settings, and the feature is positioned to reduce manual clinician adjustments while improving patient start and long‑term use. ResMed’s stated advantages align with a large addressable market (an estimated 61 million U.S. OSA patients today, projected to 77 million by 2050) and a $7.11 billion global device market in 2025 with ~7% CAGR to 2034.

Shares fell 2.5% to $250.04 on the announcement despite a $37.44 billion market cap and a Zacks FY2026 EPS consensus implying 13.2% growth; key execution risks are constrained initial availability to new myAir/AirSense 11 users, the retrospective (not prospective) nature of supporting data, and the need for clinician/reimbursement adoption to drive material revenue upside.

Key Decisions for Investors

• Consider opportunistic accumulation on material near‑term weakness given FDA clearance, differentiated AI positioning, large addressable market and a Zacks FY2026 EPS consensus implying 13.2% growth, but size exposure incrementally and tie conviction to commercial metrics
• Track rollout KPIs closely—adoption rates in the early 2026 myAir/AirSense 11 beta, measured adherence gains versus defaults, clinician uptake and any prospective clinical or reimbursement signals—and reprice the thesis if these do not materialize
• Prepare to trim or hedge positions if the limited initial rollout, failure to replicate retrospective gains prospectively, or adverse reimbursement/competitive developments emerge, otherwise maintain a constructive medium‑term stance predicated on successful commercialization